LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Lista de Ações・MannKind Corp

MannKind Corp

Fechado

SetorSaúde

3.36 1.82

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.3

Máximo

3.45

Indicadores-chave
By Trading Economics
Rendimento	-671K -17M
Vendas	-22M 90M
P/E Médio do Setor	140.5 49.701
EPS	-0.02
Margem de lucro	-18.431
Funcionários	591
EBITDA	5.9M 3.4M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+127.79% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	56M 924M
Abertura anterior	1.54
Fecho anterior	3.36

Sentimento de Notícias

By Acuity

60%

40%

291 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

4.079 / 4.323 Suporte e Resistência

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de mai. de 2026, 16:33 UTC

Ganhos

Grandes Movimentos do Mercado

Webull Shares Slide on 1Q Loss, Soaring Costs

22 de mai. de 2026, 21:10 UTC

Ganhos

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de mai. de 2026, 19:47 UTC

Ganhos

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 de mai. de 2026, 19:17 UTC

Conversa de Mercado

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 de mai. de 2026, 19:10 UTC

Conversa de Mercado

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 de mai. de 2026, 18:54 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

22 de mai. de 2026, 18:54 UTC

Conversa de Mercado

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 de mai. de 2026, 18:38 UTC

Conversa de Mercado

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 de mai. de 2026, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 de mai. de 2026, 18:09 UTC

Conversa de Mercado

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 de mai. de 2026, 17:58 UTC

Conversa de Mercado

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 de mai. de 2026, 17:54 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

22 de mai. de 2026, 17:54 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 de mai. de 2026, 17:54 UTC

Conversa de Mercado

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 de mai. de 2026, 17:03 UTC

Conversa de Mercado

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 de mai. de 2026, 16:54 UTC

Conversa de Mercado

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

22 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

22 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

22 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de mai. de 2026, 16:16 UTC

Conversa de Mercado

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

22 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 de mai. de 2026, 15:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 de mai. de 2026, 15:42 UTC

Conversa de Mercado

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 de mai. de 2026, 15:35 UTC

Conversa de Mercado

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

127.79% parte superior

Previsão para 12 meses

Média 7.54 USD 127.79%

Máximo 10 USD

Mínimo 4.75 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para MannKind Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

4.079 / 4.323Suporte e Resistência

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentimento

By Acuity

291 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.